Provectus to Present at the NYSSA 12th Annual Biotech and Specialty Pharma Conference on December 2, 2008
Mon Nov 24, 2:54 PMKNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, will present at the NYSSA 12th Annual Biotech and Specialty Pharma Conference in New York on December 2, 2008. The conference is being held at 1177 Avenue of the Americas, 2nd floor, New York City.
Craig Dees, PhD, Chairman and CEO, is scheduled to present at 10:55 a.m., EST that day. Interested investors can access a live webcast of the presentation, and are asked to follow the instructions on the NYSSA website; the link to the webcast is:
The webcast will be available for 30 days following the presentation.
Provectus recently announced the opening of its sixth site for the Phase 2 clinical trial of the Company’s lead oncology agent PV-10, at the California Pacific Medical Center in San Francisco. The Company’s other sites include Sydney, Brisbane and Adelaide in Australia, as well as M.D. Anderson in Houston, TX, and St. Luke's Hospital & Health Network, in Bethlehem, PA. The Company expects to continue expansion of the study to include sites in other major population centers in Australia as well as at least one more site in the United States over the next several months.
Provectus Pharmaceuticals’ PV-10 has been granted orphan drug designation from the FDA for its metastatic melanoma indication. Phase 2 clinical testing of PV-10 is designed to assess the agent as a treatment for Stage III and IV metastatic melanoma, the most aggressive and deadly form of skin cancer. The multi-center study will evaluate efficacy of PV-10 in a total of 80 subjects. In the study, PV-10 is being injected into up to 20 tumors in each subject. Additional treatment with PV-10 may be made 8 to 16 weeks after this initial injection, if deemed necessary by the investigator. Response will be observed for one (1) year, allowing data to be gathered for assessment of objective response rate, progression free survival, quality of life and safety. An interim assessment of safety and efficacy will be conducted after treatment of the first 20 and first 40 subjects. Details of the study are available at the www.ClincalTrials.gov clinical trials registry.
About Provectus Pharmaceuticals, Inc. (www.pvct.com)
Provectus Pharmaceuticals is a development stage company that specializes in oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. Provectus is currently conducting Phase 2 clinical trials of its proprietary drugs PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for psoriasis and atopic dermatitis. Information about these and the Company’s other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. The Company has received orphan drug designation from the FDA for its melanoma indication. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices and biotechnology. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.
Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, CFO,
866-594-5999 #30
or
Porter, LeVay & Rose, Inc.
Marlon
Nurse, VP – Investor Relations
Bill Gordon, SVP – Media Relations
212-564-4700
136.40 (1.48%)
